Randomized phase 3 trial of ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX) - Burchert, Andreas; Nicolini, Franck E.; le Coutre, Philipp; Saußele, Susanne; Hochhaus, Andreas; Tuere, Evin; Metzelder, Stephan K.; Pauck, Kim; Garn, Holger; Raifer, Hartmann; Huber, Magdalena; Gattermann, Norbert; et al. (Leukemia, 2026)
Gesehen am 05.02.2026